Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent.

Suppr

超能文献

作者信息

Eldred C D, Evans B, Hindley S, Judkins B D, Kelly H A, Kitchin J, Lumley P, Porter B, Ross B C, Smith K J

机构信息

Department of Medicinal Chemistry, Glaxo Research and Development Ltd., Ware, England.

出版信息

J Med Chem. 1994 Nov 11;37(23):3882-5. doi: 10.1021/jm00049a006.

DOI:10.1021/jm00049a006

PMID:7966149

Abstract

摘要

相似文献

Orally active non-peptide fibrinogen receptor (GpIIb/IIIa) antagonists: identification of 4-[4-[4-(aminoiminomethyl)phenyl]-1-piperazinyl]-1-piperidineacetic acid as a long-acting, broad-spectrum antithrombotic agent.

J Med Chem. 1994 Nov 11;37(23):3882-5. doi: 10.1021/jm00049a006.

New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.新型口服活性非肽类纤维蛋白原受体（GpIIb-IIIa）拮抗剂：3-[N-[4-[4-[氨基[(乙氧羰基)亚氨基]甲基]苯基]-1,3-噻唑-2-基]-N-[1-[(乙氧羰基)甲基]哌啶-4-基]氨基]丙酸乙酯（SR 121787）作为一种强效长效抗血栓形成药物的鉴定。

J Med Chem. 1997 Oct 10;40(21):3393-401. doi: 10.1021/jm970240y.

Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.新型血小板糖蛋白IIb/IIIa受体拮抗剂DMP 728的抗血小板和抗血栓形成疗效

Circulation. 1994 Jan;89(1):3-12. doi: 10.1161/01.cir.89.1.3.

Development of GPIIb/IIIa antagonists as antithrombotic drugs.

Trends Pharmacol Sci. 1992 Nov;13(11):413-7. doi: 10.1016/0165-6147(92)90126-q.

Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.新型血小板糖蛋白IIb/IIIa拮抗剂YM-57029的药理特性

Eur J Pharmacol. 2002 Mar 29;439(1-3):43-52. doi: 10.1016/s0014-2999(02)01415-2.

Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist.一种强效且口服活性的非肽类血小板纤维蛋白原受体（GPIIb/IIIa）拮抗剂的设计。

Bioorg Med Chem. 1994 Sep;2(9):897-908. doi: 10.1016/s0968-0896(00)82039-8.

Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist.非肽类纤维蛋白原受体拮抗剂。7. 一种强效口服活性纤维蛋白原受体拮抗剂的设计与合成。

J Med Chem. 1995 Aug 18;38(17):3332-41. doi: 10.1021/jm00017a017.

Design of a new class of orally active fibrinogen receptor antagonists.新型口服活性纤维蛋白原受体拮抗剂的设计

J Med Chem. 1998 Jul 2;41(14):2492-502. doi: 10.1021/jm9801096.

The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.两种合成糖蛋白IIb/IIIa拮抗剂Ro 43-8857和L-700,462对豚鼠和犬血小板聚集及出血的影响：Ro 43-8857具有口服活性的证据

Thromb Haemost. 1993 Nov 15;70(5):838-47.

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.非肽类糖蛋白IIb/IIIa抑制剂。17. 口服活性长效非肽类纤维蛋白原受体拮抗剂的设计与合成。

J Med Chem. 1997 Jun 6;40(12):1779-88. doi: 10.1021/jm9608117.

引用本文的文献

A general chemical principle for creating closure-stabilizing integrin inhibitors.一种创建稳定整合素抑制剂的一般化学原理。

Cell. 2022 Sep 15;185(19):3533-3550.e27. doi: 10.1016/j.cell.2022.08.008.

A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins.RGD 结合整合素配体的活性和选择性特征的综合评价。

Sci Rep. 2017 Jan 11;7:39805. doi: 10.1038/srep39805.

Elucidation of a common structure of selective fibrinogen receptor antagonists.选择性纤维蛋白原受体拮抗剂共同结构的阐明。

J Comput Aided Mol Des. 1998 Nov;12(6):533-42. doi: 10.1023/a:1008024924329.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验